People on the Move
Catalyst
Mid-sized biopharma Catalyst, which develops therapies for rare autoimmune diseases, has appointed David Muth to Executive Vice President of Corporate Development. Muth will report to Patrick McEnany, CEO.
The new role makes Muth responsible for all of Catalyst's corporate development activities, invluding a commercialization strategy for Firdapse, the company’s treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), currently in Phase III and under Breakthrough Therapy Designation by the US FDA.
Muth has over 35 years of experience in the biotechnology and pharmaceutical business. Most recently he served, from 2010 to 2014, as the President and CEO of Croma Pharmaceuticals, where he established North American operations and launched 10 Ocular Surgical products.
Before joining Croma, the new VP held senior roles at Bausch + Lomb, Avalon, Osmotica, Cengent Therapeutics, Nabi Biopharmaceutical, and Johnson & Johnson.
(Picture credit: Aki Hannenen)